Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

高剂量阿糖胞苷治疗复发/难治性急性髓系白血病后进行派姆单抗 II 期临床试验

阅读：7

作者：Joshua F Zeidner, Benjamin G Vincent, Anastasia Ivanova, Dominic Moore, Karen P McKinnon, Alec D Wilkinson, Rupkatha Mukhopadhyay, Francesco Mazziotta, Hanna A Knaus, Matthew C Foster, Catherine C Coombs, Katarzyna Jamieson, Hendrik Van Deventer, Jonathan A Webster, Gabrielle T Prince, Amy E DeZern,

期刊：

Blood Cancer Discovery

影响因子：

11.500

时间：

2021

起止号：

2021 Sep 10;2(6):616-629.

doi：

10.1158/2643-3230.BCD-21-0070

研究方向：

肿瘤

疾病类型：

白血病

Significance

Immune-checkpoint blockade with pembrolizumab was tolerable and feasible after high-dose cytarabine in R/R AML, with encouraging clinical activity, particularly in refractory AML and those receiving treatment as first salvage regimen. Further study of pembrolizumab and other immune-checkpoint blockade strategies after cytotoxic chemotherapy is warranted in AML.See related commentary by Wei et al., p. 551. This article is highlighted in the In This Issue feature, p. 549.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。

2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。

4、投稿及合作请联系：info@biocloudy.com。